Headlines proclaimed a potential game changer in treating cardiovascular disease—Vascepa—and company shares quickly soared, but the study behind the claim remains a mystery.
The arrival of Radicava for ALS marks the first new drug in the market for this rare disease since 1995.
How can one possibly deny a dying patient even the slightest chance of prolonged life or recovery? Is there a side effect worse than certain death?
The latest statistics come as authorities in several parts of the United States grapple with opioid and heroin crises.